---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-058698"
form_type: "8-K"
ticker: null
cik: "0000727207"
company_name: "Accelerate Diagnostics, Inc"
filed_at: "2024-05-08T23:59:59+00:00"
generated_at: "2026-06-02T14:37:42.353318+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Accelerate Diagnostics reports preliminary Q1 net loss of $17.0M; Wave trial on track

## Summary
- Q1 net sales $2.9M (+4% YoY); gross margin 25% vs 36% due to lower capital instrument mix.
- Net loss $17.0M ($0.88 per share); cash used $9.0M net of financing, including ~$1M prepaid annual expenses.
- Pre-clinical trial site installed for Accelerate Wave system; Gram Positive PBC menu development begun.
- Contracts secured covering ~70% of U.S. Pheno base; 12 new Pheno instruments added; 348 revenue-generating instruments at quarter-end.
- SG&A fell to $5.7M from $10.1M; R&D to $5.2M from $7.0M; both reflect lower employee costs.

## SEC filing metadata
- accession: 0001104659-24-058698
- form_type: 8-K
- cik: 0000727207
- company_name: Accelerate Diagnostics, Inc
- filed_at: 2024-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/727207/000110465924058698/0001104659-24-058698-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/727207/000110465924058698/tm2413892d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-058698
- JSON: https://secwatch.observer/filing/0001104659-24-058698.json
- Plain text: https://secwatch.observer/filing/0001104659-24-058698.txt

## Key facts
- Earnings Releases
  Accelerate Diagnostics, Inc reported first quarter ended March 31, 2024 results: revenue $2.9 million, net income Net loss was $17.0 million, EPS $0.88 net loss per share.
  - Period: first quarter ended March 31, 2024
  - Revenue: $2.9 million
  - Net income: Net loss was $17.0 million
  - EPS: $0.88 net loss per share
  - Result: preliminary results
  source text: and another 75 contracted instruments in the process of being implemented. First Quarter 2024 Preliminary Financial Highlights § Net sales for the quarter were $2.9 million, compared to $2.8 million for the same quarter of the prior year. Revenues from consumable products increased by 7% compared to the same period in the prior year. § Gross margin
  evidence_url: https://www.sec.gov/Archives/edgar/data/727207/000110465924058698/0001104659-24-058698-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.